Literature DB >> 11306387

Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer.

M Han1, S Piantadosi, M L Zahurak, L J Sokoll, D W Chan, J I Epstein, P C Walsh, A W Partin.   

Abstract

OBJECTIVES: Serum acid phosphatase (ACP) was once used as the marker for advanced prostate cancer. However, with the development of assays for prostate-specific antigen (PSA), a more sensitive and specific tumor marker, the use of ACP has diminished. We investigated the prognostic value of preoperative serum ACP in predicting prognosis for men with localized prostate cancer following radical retropubic prostatectomy (RRP).
METHODS: Of 2293 men treated from 1982 to 1998, 1681 men had a preoperative ACP measurement using an enzymatic assay. We analyzed the actuarial freedom from biochemical (PSA) progression following RRP according to ACP levels. We used multivariate logistic regression and proportional hazards models to determine the independent prognostic value of ACP level with respect of pathologic stage and biochemical recurrence.
RESULTS: ACP was not an independent predictor of organ confinement or lymph node involvement in the multivariate logistic regression models using preoperative variables. However, in the proportional hazards model, ACP was an independent predictor of tumor recurrence following RRP, and there was a statistically significant improvement in biochemical recurrence-free survival for men with lower levels of ACP (P <0.001). Furthermore, the normalized hazard ratios of ACP and PSA for predicting biochemical recurrence were similar.
CONCLUSIONS: Stratification of men according to their preoperative ACP levels was predictive of patient outcome after RRP. Proportional hazards modeling using preoperative variables demonstrated that the serum ACP level is an independent predictor of tumor recurrence following RRP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11306387     DOI: 10.1016/s0090-4295(00)01073-6

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine.

Authors:  Simona Principe; Yunee Kim; Simona Fontana; Vladimir Ignatchenko; Julius O Nyalwidhe; Raymond S Lance; Dean A Troyer; Riccardo Alessandro; O John Semmes; Thomas Kislinger; Richard R Drake; Jeffrey A Medin
Journal:  J Proteome Res       Date:  2012-02-29       Impact factor: 4.466

2.  Novel diagnostic biomarkers for prostate cancer.

Authors:  Chikezie O Madu; Yi Lu
Journal:  J Cancer       Date:  2010-10-06       Impact factor: 4.207

Review 3.  Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease.

Authors:  Richard R Drake; Krista Y White; Thomas W Fuller; Elena Igwe; Mary Ann Clements; Julius O Nyalwidhe; Robert W Given; Raymond S Lance; O John Semmes
Journal:  J Proteomics       Date:  2009-01-20       Impact factor: 4.044

4.  Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids.

Authors:  Krista Y White; Lucy Rodemich; Julius O Nyalwidhe; Mary Ann Comunale; Mary Ann Clements; Raymond S Lance; Paul F Schellhammer; Anand S Mehta; O John Semmes; Richard R Drake
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

5.  Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype.

Authors:  Hyunho Han; Hyung Ho Lee; Kwibok Choi; Young Jun Moon; Ji Eun Heo; Won Sik Ham; Won Sik Jang; Koon Ho Rha; Nam Hoon Cho; Filippo G Giancotti; Young-Deuk Choi
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-04-26       Impact factor: 5.455

6.  Markers for detection of prostate cancer.

Authors:  Raymond A Clarke; Horst J Schirra; James W Catto; Martin F Lavin; Robert A Gardiner
Journal:  Cancers (Basel)       Date:  2010-06-04       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.